Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results
Top Cited Papers
- 6 February 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (2) , 443-454
Abstract
Compromised vascular endothelial barrier function is a salient feature of diabetic complications such as sight-threatening diabetic macular edema (DME). Current standards of care for DME manage aspects of the disease, but require frequent intravitreal administration and are poorly effective in large subsets of patients. Here we provide evidence that an elevated burden of senescent cells in the retina triggers cardinal features of DME pathology and conduct an initial test of senolytic therapy in patients with DME. In cell culture models, sustained hyperglycemia provoked cellular senescence in subsets of vascular endothelial cells displaying perturbed transendothelial junctions associated with poor barrier function and leading to micro-inflammation. Pharmacological elimination of senescent cells in a mouse model of DME reduces diabetes-induced retinal vascular leakage and preserves retinal function. We then conducted a phase 1 single ascending dose safety study of UBX1325 (foselutoclax), a senolytic small-molecule inhibitor of BCL-xL, in patients with advanced DME for whom anti-vascular endothelial growth factor therapy was no longer considered beneficial. The primary objective of assessment of safety and tolerability of UBX1325 was achieved. Collectively, our data suggest that therapeutic targeting of senescent cells in the diabetic retina with a BCL-xL inhibitor may provide a long-lasting, disease-modifying intervention for DME. This hypothesis will need to be verified in larger clinical trials. ClinicalTrials.gov identifier: NCT04537884.Keywords
Funding Information
- Diabetes Canada (DI-3-18-5444-PS)
- Gouvernement du Canada | Canadian Institutes of Health Research (#353770)
- Unity Biotechnology
- Santé
- Montreal Diabetes Research Center
This publication has 68 references indexed in Scilit:
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- Targeted deletion of Vegfa in adult mice induces vision lossJournal of Clinical Investigation, 2012
- Protein Kinase Cβ Phosphorylates Occludin Regulating Tight Junction Trafficking in Vascular Endothelial Growth Factor–Induced Permeability In VivoDiabetes, 2012
- TheRd8Mutation of theCrb1Gene Is Present in Vendor Lines of C57BL/6N Mice and Embryonic Stem Cells, and Confounds Ocular Induced Mutant PhenotypesInvestigative Ophthalmology & Visual Science, 2012
- Clearance of p16Ink4a-positive senescent cells delays ageing-associated disordersNature, 2011
- Multi-Modal Proteomic Analysis of Retinal Protein Expression Alterations in a Rat Model of Diabetic RetinopathyPLOS ONE, 2011
- Regulation of Cyr61/CCN1 expression by hypoxia through cooperation of c-Jun/AP-1 and HIF-1α in retinal vascular endothelial cellsExperimental Eye Research, 2010
- Occludin Phosphorylation and Ubiquitination Regulate Tight Junction Trafficking and Vascular Endothelial Growth Factor-induced PermeabilityJournal of Biological Chemistry, 2009
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor SuppressorPLOS Biology, 2008
- Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and PhotoreceptorsPLOS ONE, 2008